We are live on ! Find out more
ABUS icon

Arbutus Biopharma
ABUS

65 hedge funds and large institutions have $75.5M invested in Arbutus Biopharma in 2020 Q3 according to their latest regulatory filings, with 30 funds opening new positions, 9 increasing their positions, 16 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

88% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 16

59% more capital invested

Capital invested by funds: $47.6M → $75.5M (+$28M)

27% more funds holding

Funds holding: 51 → 65 (+14)

8.76% less ownership

Funds ownership: 37.88% → 29.12% (-8.8%)

20% less call options, than puts

Call options by funds: $1.5M | Put options by funds: $1.87M

44% less repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 16

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
65
Holders Change
+14
Holders Change %
+27.45%
% of All Funds
1.31%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
30
Increased
9
Reduced
16
Closed
16
Calls
$1.5M
Puts
$1.87M
Net Calls
-$373K
Net Calls Change
-$1.58M

Top Buyers

Rank Fund Capital Flow
1
FCMI
Foresite Capital Management IV
California
+$10.1M
2
TI
Think Investments
California
+$6.08M
3
BlackRock
BlackRock
New York
+$2.53M
4
Ameriprise
Ameriprise
Minnesota
+$1.99M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$1.26M

Top Sellers

Rank Fund Capital Flow
1
CAC
Cowen and Company
New York
-$11.7M
2
Goldman Sachs
Goldman Sachs
New York
-$4.29M
3
Citadel Advisors
Citadel Advisors
Florida
-$3.89M
4
RI
RTW Investments
New York
-$2.71M
5
Morgan Stanley
Morgan Stanley
New York
-$1.35M
Name Holding Trade Value Shares
Change 		Change in
Stake
CG
51
Cutler Group
California
$16K +$15.8K +5,200 New
TRCT
52
Tower Research Capital (TRC)
New York
$14K -$21.1K -6,941 -61%
SIAP
53
Sterling Investment Advisors (Pennsylvania)
Pennsylvania
$13K – – –
Bank of America
54
Bank of America
North Carolina
$9K -$157K -51,598 -95%
Bank Julius Baer & Co
55
Bank Julius Baer & Co
Switzerland
$5K +$4.56K +1,500 New
FDCDDQ
56
Federation des caisses Desjardins du Quebec
Quebec, Canada
$2.5K – – –
HIA
57
Harbor Investment Advisory
Maryland
$2K -$1.52K -500 -50%
RG
58
Retirement Group
California
$2K +$1.52K +500 New
PA
59
Parallel Advisors
California
$2K +$1.67K +550 New
TF
60
TimeScale Financial
Massachusetts
$1K – – –
NFG
61
Next Financial Group
Texas
$1K +$608 +200 New
AF
62
Advisornet Financial
Minnesota
$1K +$827 +272 New
Jennison Associates
63
Jennison Associates
New York
– -$618K -339,639 Closed
Squarepoint
64
Squarepoint
New York
– -$586K -322,225 Closed
Two Sigma Investments
65
Two Sigma Investments
New York
– -$516K -283,507 Closed
Millennium Management
66
Millennium Management
New York
– -$405K -222,573 Closed
Arrowstreet Capital
67
Arrowstreet Capital
Massachusetts
– -$113K -62,321 Closed
Renaissance Technologies
68
Renaissance Technologies
New York
– -$111K -61,207 Closed
Russell Investments Group
69
Russell Investments Group
United Kingdom
– -$78K -43,100 Closed
Creative Planning
70
Creative Planning
Kansas
– -$60K -32,748 Closed
VF
71
Virtu Financial
New York
– -$31K -17,147 Closed
ARTA
72
A.R.T. Advisors
New York
– -$26K -14,140 Closed
CSS
73
Cubist Systematic Strategies
Connecticut
– -$23K -12,562 Closed
WS
74
Wedbush Securities
California
– -$20K -11,000 Closed
FIA
75
FNY Investment Advisers
New York
– -$18K -9,900 Closed
1 2
3
4

ABUS Hedge Fund Activity: Q3 2020 in Review

65 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q3 2020, worth a combined $75.5M — up 59% from $47.6M a quarter earlier.

Buyers outnumbered sellers: 30 funds opened new ABUS positions and 16 closed out — a net gain of 14 holders — while 9 added to existing stakes and 16 trimmed.

The largest buyer was Foresite Capital Management IV, opening a new position worth an estimated $10.1M. The largest seller was Cowen and Company, cutting an estimated $11.7M.

  • 65 institutional investors held Arbutus Biopharma (ABUS) as of Q3 2020, up from 51 in Q2 2020.
  • Funds reported $75.5M of Arbutus Biopharma stock for Q3 2020, up 59% quarter-over-quarter.
  • 30 funds opened new Arbutus Biopharma positions in Q3 2020 and 16 closed out, a net change of +14 holders.
  • The largest Arbutus Biopharma buyer in Q3 2020 was Foresite Capital Management IV, an estimated $10.1M added.
  • The largest Arbutus Biopharma seller in Q3 2020 was Cowen and Company, an estimated $11.7M sold.

Based on aggregated 13F filings for Q3 2020.